Update on the Polish dermocosmetics and biotech company PHARMENA S.A.
PHARMENA is a Polish company, which has developed the patented 1-MNA substance. It offers dermocosmetics and is working on a 1-MNA dietary supplement as well as a 1-MNA drug. The drug completed Phase II of clinical research in 2016. ​
Pharmena SA is a Poland-based producer of cosmetics and pharmaceuticals. The Company's products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.
We are a leading, management-owned research boutique with a focus on companies from Emerging Europe. Our role is that of an intermediary between companies on the one hand and investors on the other. Our research products are directly distributed to more than 200 mutual and pension funds, family offices and independent asset managers from Central and Eastern Europe, the German-speaking region, Scandinavia, France and UK. In addition, we publish our reports on platforms such as Bloomberg, Thomson Reuters, Capital IQ and PAP, thus ensuring that they are available to institutions from around the world. By organising roadshows and conferences, we provide investors with direct access to corporate decision makers. Our team consists of professionals with long capital market experience in both Western Europe and the CEE region.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.